Clinical Endocannabinoid Deficiency (CED) Revisited: Ethan Russo @medicinal.genomics

Uploaded August 2026 | Updated September 2026, 2 weeks ago

Dr. Ethan Russo (CReDO Science) presents "Clinical Endocannabinoid Deficiency (CED) Revisited" at CannMed 2026, covering migraine, fibromyalgia, irritable bowel syndrome, PTSD, and cannabinoid therapeutics.

This presentation examines the evidence that migraine, fibromyalgia, irritable bowel syndrome, major depression, post-traumatic stress, and other conditions are related to deficiencies in endocannabinoid tone, along with their implications for therapeutic management.

Dr. Ethan Russo is the Founder and CEO of CReDO Science.

This talk was part of the CannMed Medical Practicum, a full-day educational program for clinicians and professionals expanding their expertise in medical cannabis, covering the endocannabinoid system, cannabinoid therapeutics, minor cannabinoids, product formulation, and more, led by a faculty of internationally recognized physicians and researchers.

This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.

Clinical Endocannabinoid Deficiency (CED) Revisited: Ethan Russo

What are pyrocannabinoids? - Kristofer Marsh, PhD

What Is Hop Latent Viroid? Why Has It Become a Challenge for the Cannabis Industry?

$Root & Bloom 3x Harvest Yield with In-House Pathogen Testing Root & Bloom, a commercial cannabis cultivator based in Salisbury, MA, was experiencing persistent root health issues, elevated clone losses, and inconsistent production that limited room-level yield to approximately 100 lbs per harvest. By implementing in-house qPCR testing, the team was able to eliminate plants infected with Fusarium and Pythium and trace the contamination source to the incoming water supply. This discovery prompted the cultivation team to redesign their irrigation system and implement key operational changes to prevent future infections. Key Outcomes: 3x increase in room-level yield (104 lbs to 325 lbs) 66% reduction in clone losses pre cycle (70 to 20) Replaced $4,000/week in off-site testing with in-house testing at a fraction of the cost Same-day results on up to 70 samples per run Download the Case Study: https://medicinalgenomics.com/resource/root-and-bloom-triple-yield/$

High-Throughput Screening and AI-Driven Discovery of Therapeutic Cannabinoids, Terpenoids, and...

Unlocking The Cannabis Genome - CannMed 25 Innovation & Investment Summit

Is There A Lack of Product Recall Reporting? - Sherman Hom, PhD

Why Explore Cannabinoids as an Alternative to Sleep Medicine for Children with ASD? - Mohsin Maqbool

Why is opioid respiratory induced depression a critical target for overdose prevention? - Beth Wiese

What changed in the smoked isolates vs isolate itself? - Kristofer Marsh, PhD

CannMed 26 Innovation & Collaboration Summit | June 15-18, 2026 | Hyatt Regency Lake Tahoe Resort

The Impact of Cannabinoids on Prostate Cancer! - Dr. Shiksha Gallow